Webinar: Preclinical Immunogenicity Risk Assessment of Biotherapeutics Supports Improved Safety, Efficacy and Development Costs

Date: 02 December 2015 Location: Online Event City: Online Event Country: Online Event

Join Life Science Leader and Lonza for a webinar:  Preclinical Immunogenicity Risk Assessment of Biotherapeutics Supports Improved Safety, Efficacy and Development Costs

 

At least nine out of ten drug candidates fail during development. Of those that reach registration, only one in five recovers the average investment made in its development. This is why it is becoming essential to incorporate novel methodologies to reduce preclinical and clinical failures by facilitating early decision making before expensive investments have been made. Among the primary causes for attrition in early clinical development are safety and pharmacology issues. In the case of biopharmaceuticals, immunogenic and hypersensitivity reactions are perhaps the largest contributors to such early clinical failures. Being able to predict such adverse reactions is often a challenge that cannot be easily achieved using traditional animal models.

This webinar will outline our immunogenicity assessment platforms and will include:

  • Prediction of HLA binding using high throughput tools
  • Identification of naturally processed HLA binding peptides
  • T cell epitope screening
  • Assessment of CD4+ and CD8+ T cell responses to whole proteins
  • Pre-existing B cell responses
  • Cytokine profiling

 

Register Here to join the webinar on December 2, 2015 at 11:00 am EST.

Bg